XPOVIO® Approved in Hong Kong for Two Additional Indications in Multiple Myeloma and Diffuse Large B-Cell Lymphoma
- XPOVIO® (selinexor) has received approvals for three indications in Hong Kong. These include its previous approval as the treatment for multiple myeloma (MM) when used together with dexamethasone (Xd), and its recent approvals as a monotherapy for relapsed or refractory diffuse large B-cell lymphoma (R/RDLBCL) and as a combination therapy when...
S3 Connected Health Receives Frost & Sullivan’s 2025 Global Company of the Year Recognition for Excellence in Medical Device Connectivity
Recognized for pioneering advancements that redefine medical device connectivity, accelerate home-based care, and deliver transformative value across global healthcare ecosystems. SAN ANTONIO, Dec. 3, 2025 /PRNewswire/ -- Frost & Sullivan is pleased to announce that S3 Connected Health has received the 2025 Global Company of the Year Recognition in the Medical Device Connectivity (MDC) industry for its outstanding achievements in driving...
Waterdrop Wins 2025 Global Best Case Brands Award, Empowering Inclusive Protection Through Technological Innovation
BEIJING, Dec. 3, 2025 /PRNewswire/ -- Waterdrop Inc. (NYSE: WDH) was honored with the Global Best Case Brands Award at the 3rd International Conference on Management Change and Sustainable Development (MC&SD). Selected from more than 100 nominated companies, Waterdrop stood out for its significant contributions and innovative practices in advancing inclusive protection. The conference was hosted by Jiangxi University...
World-Leading Microsurgeon Professor J.P. Hong Joins MediThinQ as CMO, Marking Strong Validation for Next-Generation Digital Microsurgery
SINGAPORE, Dec. 3, 2025 /PRNewswire/ -- MediThinQ, a fast-growing innovator in surgical displays and digital 3D microscopy, today announced that world-renowned reconstructive microsurgeon Prof. Joon-pio Hong has joined the company as Chief Medical Officer. His decision marks one of the strongest clinical endorsements to date for MediThinQ's next-generation digital microsurgery platform, SHIYA 20. Prof. Joon-pio...
Celltrion announces U.S. FDA approval of 300mg strength of OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®
FDA approval of OMLYCLO® (omalizumab-igec) 300 mg/2 mL solution in a single-dose prefilled syringe for subcutaneous injection expands dosing flexibility and supports tailored treatment for individual patients with certain allergic diseases OMLYCLO® (omalizumab-igec) is the first and only biosimilar designated as interchangeable with XOLAIR® (omalizumab); The FDA previously approved OMLYCLO®...
THE U.S. POINTER STRUCTURED HEALTHY LIFESTYLE PROGRAM — PREVIOUSLY SHOWN TO IMPROVE COGNITION — MAY ALSO IMPROVE SLEEP APNEA, BLOOD PRESSURE REGULATION, AND COGNITIVE RESILIENCE
- Two-year lifestyle intervention "recipe" tested in three NIH-funded ancillary studies - Key Takeaways Findings from three NIA-funded ancillary studies to the U.S. POINTER trial described beneficial effects as measured by brain imaging, sleep health, and blood pressure regulation. The U.S. POINTER recipe, a 2-year multicomponent healthy lifestyle intervention with regular structured support,...
Natural Field Releases “Ashwagandha White Paper” and Landmark Liposome Research Achievements at 2025 FTA (Food Research Exchange Super Ingredients Conference)
HANGZHOU, China, Dec. 3, 2025 /PRNewswire/ -- Against the backdrop of the accelerated upgrading of the global functional nutrition industry, technology-driven ingredient enterprises are increasingly emerging as the core force of the industrial chain. In November 2025, the FTA (Food Research Exchange Super Ingredients Conference) was successfully held in Hangzhou, gathering renowned enterprises from the fields of functional foods, nutritional...
TraceLink Announces 2025 Corporate Grant Recipients Driving Global Community Impact
Through this annual program, TraceLink champions global health equity, community resilience, and shared purpose SummaryTraceLink announced the eight global nonprofit recipients of its 2025 corporate grant program, supporting organizations in the U.S., India, and Spain and providing volunteer opportunities for employees. Built on its mission to enhance health, safety, and the...
Lunit to Highlight New AI Evidence in Cancer Screening and Breast Density-Driven Risk Modeling at RSNA 2025
Eight oral presentations and six posters demonstrate advances in mammography, DBT performance, and density-informed risk modeling SEOUL, South Korea, Dec. 2, 2025 /PRNewswire/ -- Lunit, a leading provider of AI for cancer diagnostics and precision oncology, today announced it will present 14 studies at the Radiological Society of North America (RSNA) 2025...
Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities
SYDNEY, Dec. 2, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced that it has entered into a securities purchase agreement with certain established institutional and accredited investors for a private placement of equity securities (PIPE). Pursuant to the securities purchase agreement, the Company agreed to offer and sell to the investors an...
